Early observations indicated numerous objective responses in patients with melanoma, gallbladder adenocarcinoma, mesothelioma, non-small-cell lung cancer, and malignant peripheral nerve sheath tumors in the presence of MTAP deletion. Here, MTAP is linked to melanoma.